What are the recommended concentration, maximum dose, and monitoring guidelines for an injection of bupivacaine in an adult patient without known hypersensitivity to amide‑type local anesthetics?

Bupivacaine Injection: Dosing, Concentration, and Monitoring

For adult patients without contraindications, use bupivacaine at a maximum dose of 2.5 mg/kg (without epinephrine) or 3.0 mg/kg (with epinephrine), with common concentrations of 0.25% for most regional blocks and infiltration. 1

Maximum Dosing Guidelines

Adults

• Without epinephrine: Maximum 2.5 mg/kg 1
• With epinephrine: Maximum 3.0 mg/kg 1

These doses apply to single-injection techniques for peripheral nerve blocks and wound infiltration. The addition of epinephrine allows for a 20% dose increase due to reduced systemic absorption.

Concentration Selection by Procedure

For wound infiltration and peripheral nerve blocks:

• Use 0.25% bupivacaine (2.5 mg/mL) at maximum 1 mL/kg (= 2.5 mg/kg) 2

For epidural blocks:

• Thoracic: 0.25% bupivacaine, 0.2-0.3 mL/kg (max 10 mL) initially 2
• Lumbar: 0.25% bupivacaine, 0.5 mL/kg (max 15 mL) initially 2
• Caudal: 0.25% bupivacaine, 1.0 mL/kg 2

For spinal anesthesia:

• Cesarean section: 7.5-10.5 mg (1-1.4 mL of 0.75% hyperbaric solution) 3
• Lower abdominal procedures: 12 mg (1.6 mL) 3

Critical Monitoring Requirements

Mandatory Monitoring During Administration

• Continuous monitoring of oxygen saturation, heart rate, and ventilation 1
• Cardiovascular and respiratory vital signs must be assessed continuously 3
• Patient's level of consciousness requires constant evaluation 3
• Parameters should be recorded at least every 5 minutes during deep sedation/general anesthesia, or every 10 minutes for moderate sedation 1

Safety Precautions

Always aspirate before injection to avoid intravascular administration—this is critical as a negative aspiration does not guarantee against intravascular injection 3. Inject incrementally rather than as a single bolus to detect early signs of toxicity.

Early warning signs of local anesthetic systemic toxicity (LAST):

• Restlessness, anxiety, incoherent speech
• Metallic taste, tinnitus, perioral numbness
• Lightheadedness, dizziness, blurred vision
• Tremors, twitching, drowsiness 3

Management of Local Anesthetic Systemic Toxicity

If LAST occurs, follow this protocol immediately 1:

1. Get help and ventilate with 100% oxygen; alert nearest facility with cardiopulmonary bypass capability
2. Provide airway/ventilatory support and chest compressions if needed
3. Manage seizures with benzodiazepines (midazolam 0.1-0.2 mg/kg IV); avoid propofol if cardiovascular instability present
4. Administer 20% lipid emulsion: 1.5 mL/kg over ~1 minute, repeat bolus once or twice for persistent cardiovascular collapse
5. Initiate lipid infusion: 0.25 mL/kg/min until circulation restored; double rate if blood pressure remains low
6. Continue infusion for at least 10 minutes after circulatory stability; recommended upper limit ~10 mL/kg

Important Clinical Caveats

Avoid vasopressin, calcium channel blockers, β-blockers, or additional local anesthetic during resuscitation. Reduce epinephrine dosages if needed. 1

The toxic effects of local anesthetics are additive—when combining bupivacaine with other local anesthetics or using it with sedatives/opioids, reduce the total dose accordingly. 1, 3

Lower doses in highly vascular areas where systemic absorption is increased. 1

Ensure intravenous access before administering bupivacaine for any regional technique to allow immediate treatment of complications. 3

Duration of action: Bupivacaine provides 180-600 minutes of anesthesia, making it suitable for prolonged procedures. 1